Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.82  0.02  0.70%   
About 61% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two weeks ago at zacks.com         
Arcus Biosciences, Inc. Reports Q3 Loss, Tops Revenue Estimates
zacks News
over two weeks ago at zacks.com         
Caribou Biosciences, Inc. Reports Q3 Loss, Lags Revenue Estimates
zacks News
over two weeks ago at investing.com         
Precision Biosciences general counsel sells 4,815 in stock
Investing News at Macroaxis
over three weeks ago at finance.yahoo.com         
Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates
Yahoo News
over three weeks ago at investing.com         
Harmony Biosciences director Antonio Gracias sells 139m in stock
Investing News at Macroaxis
over three weeks ago at gurufocus.com         
Castle Biosciences Inc Reports Q3 2024 Earnings Revenue Hits 85. ...
Gurufocus Stories at Macroaxis
over three weeks ago at seekingalpha.com         
Interpace Biosciences GAAP EPS of 0.31, revenue of 12.3M
seekingalpha News
over three weeks ago at seekingalpha.com         
Castle Biosciences Q3 2024 Earnings Preview
seekingalpha News
over three weeks ago at thelincolnianonline.com         
Neurocrine Biosciences Stock Rating Lowered by StockNews.com
news
over three weeks ago at gurufocus.com         
Insider Buying CFO Alan Fuhrman Acquires 9,500 Shares of Tyra Biosciences Inc
Gurufocus Stories at Macroaxis
over three weeks ago at globenewswire.com         
Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q
Macroaxis News: globenewswire.com
over three weeks ago at zacks.com         
Lisata Therapeutics, Inc. Upgraded to Buy Heres What You Should Know
zacks News
over three weeks ago at accesswire.com         
Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should C...
news
over three weeks ago at businesswire.com         
Vernal Biosciences Appoints Jim Petrilla as CEO Board Director
businesswire News
over three weeks ago at finance.yahoo.com         
Hope Biosciences Research Foundation Reports Promising Phase II Trial Results for Stem Cell Therapy ...
Yahoo News
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Castle Biosciences Inc Trading 3.24 percent Higher on Oct 29
10/29/2024
2
Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates
11/05/2024
3
Artelo Biosciences Stock Dips Amidst Financial Report
11/13/2024
4
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
11/18/2024
5
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As...
11/19/2024
6
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
11/20/2024
7
The Dr. James Morales Grant for Medicine and Biosciences Invites Undergraduate Scholars to Apply
11/21/2024
8
Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset
11/22/2024
9
Aptose Biosciences Inc. Announces Closing of 8 Million Public Offering
11/25/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Transaction History
View history of all your transactions and understand their impact on performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges